Key insights
- Hims & Hers nominated Kofi Amoo-Gottfried, former DoorDash CMO, to its board. Recent news includes expansion of platform to prescribe Eli Lilly's weight loss medications, leading to price target increases from BofA Securities and JPMorgan. This signals potential growth and positive market sentiment for HIMS.
SAN FRANCISCO - Hims & Hers Health, Inc. (NYSE:HIMS) nominated Kofi Amoo-Gottfried for election as a director at the company’s annual shareholder meeting in June, according to a press release statement.
Amoo-Gottfried served as Chief Marketing Officer at DoorDash and held leadership positions at Meta. He has worked at marketing agencies including Leo Burnett, Wieden + Kennedy, and Publicis, where he established the company’s first owned agency in Central & West Africa. He currently serves on the boards of StitchFix and Vital Farms.
The company also nominated eight returning board members for election: Andrew Dudum, CEO of Hims & Hers; Deb Autor, former FDA deputy and Chief Policy Officer of Hims & Hers; Dr. Toby Cosgrove, former CEO of the Cleveland Clinic; Anja Manuel, international regulatory and foreign policy expert; Christopher Payne, tech industry leader; Andrea Perez, President of FP Movement and former Nike and Sony marketing executive; Kåre Schultz, former pharmaceutical industry chief; and David Wells, former CFO of Netflix.
Christiane Pendarvis and Dr. Pat Carroll will not stand for re-election at the 2026 annual meeting. The board size will decrease to nine members following the election. Dr. Carroll will continue as the company’s Global Chief Medical Officer.
The shareholder vote on the director nominations will take place at the company’s annual meeting in June.
In other recent news, Hims & Hers Health has made significant strides with its earnings and partnerships. The company expanded its platform to allow providers to prescribe Eli Lilly’s weight loss medications, such as Zepbound and Foundayo, to customers, enhancing access to FDA-approved GLP-1 medications. This development follows a partnership expansion with Eli Lilly, which also led BofA Securities to raise its price target on Hims & Hers stock to $32, maintaining a Neutral rating. Meanwhile, JPMorgan initiated coverage on Hims & Hers with an Overweight rating and a price target of $35, reflecting optimism about the company’s GLP-1 product offerings.
However, competition is intensifying as Amazon launched a weight management program through Amazon One Medical, which includes GLP-1 medications, impacting Hims & Hers stock. Despite this, Leerink Partners reiterated a Market Perform rating with a $25 price target, noting potential growth from an upcoming Advisory Committee meeting on injectable peptides. These recent developments highlight the dynamic landscape Hims & Hers is navigating in the healthcare sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.